Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
2.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Br J Cancer
; 124(2): 391-398, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33020594
3.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 190-199, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824476
4.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Lancet Oncol
; 21(9): 1234-1243, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818466
5.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(3): 465, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079081
6.
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Res
; 15(5): R86, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24060333
7.
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
J Exp Clin Cancer Res
; 41(1): 189, 2022 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35655320
8.
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Breast Cancer Res Treat
; 125(2): 447-55, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21107682
9.
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Clin Cancer Res
; 27(2): 418-428, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887722
10.
PD-1 Blockade in Anaplastic Thyroid Carcinoma.
J Clin Oncol
; 38(23): 2620-2627, 2020 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32364844
11.
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
Nat Clin Pract Oncol
; 6(2): 93-104, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19107109
12.
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Clin Breast Cancer
; 7(4): 321-5, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17092399
13.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
J Clin Oncol
; 34(18): 2115-24, 2016 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091708
14.
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
J Clin Oncol
; 33(19): 2158-65, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26014300
15.
Targeting mTOR pathways in human malignancies.
Curr Pharm Des
; 18(19): 2766-77, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22475451
16.
Current and future directions in mammalian target of rapamycin inhibitors development.
Expert Opin Investig Drugs
; 20(3): 381-94, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21299441
17.
Translational research in phase I trials.
Clin Transl Oncol
; 11(9): 580-8, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19775997
18.
mTOR inhibitors in the treatment of cancer.
Expert Opin Investig Drugs
; 17(11): 1717-34, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18922108